adjuvant;
breast cancer;
docetaxel;
paclitaxel;
differentiation;
D O I:
10.1634/theoncologist.6-suppl_3-1
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Docetaxel and paclitaxel differ in their precise molecular targets and pharmacokinetics. Docetaxel is more avidly taken up by tumor cell lines than paclitaxel, and its efflux is slower. Comparative cytotoxicity data suggest greater potency. These factors may help explain the clinical differences that have been observed between the taxanes in patients with breast cancer.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 24 条
[1]
BELLOT R, 1998, P AN M AM SOC CLIN, V17, pA221